{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:41:13Z","timestamp":1778640073246,"version":"3.51.4"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_138097\/1"],"award-info":[{"award-number":["310030_138097\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DML"],"published-print":{"date-parts":[[2020,1,15]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Cancer cells undergo genetic and environmental changes that can alter cellular\ndisposition of drugs, notably by alterations of transmembrane drug transporters expression. Whether the\ninflux organic cation transporter 1 (OCT1) encoded by the gene SLC221A1 is implicated in the cellular\nuptake of imatinib is still controversial. Besides, imatinib ionization state may be modulated by the hypoxic\nacidic surrounding extracellular microenvironment.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Objective: <\/jats:title>\n<jats:p>To determine the functional contribution of OCTs and extracellular pH on imatinib cellular\ndisposition.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> We measured imatinib uptake in two different models of selective OCTs drug transporter expression\n(transfected Xenopus laevis oocytes and OCT-expressing HEK293 human cells), incubated at\npH 7.4 and 6, using specific mass spectrometry analysis.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Imatinib cellular uptake occurred independently of OCT1- OCT2- or OCT3-mediated drug\ntransport at pH 7.4. Uptake of the OCTs substrate tetraethylammonium in oocytes remained intact at\npH 6, while the accumulation of imatinib in oocytes was 10-fold lower than at pH 7.4, irrespectively of\nOCTs expressions. In OCT1- and OCT2-HEK cells at pH 6, imatinib accumulation was reduced by 2-\n3-fold regardless of OCTs expressions. Since 99.5% of imatinib at pH6 is under the cationic form, the\nreduced cellular accumulation of imatinib at such pH may be explained by the lower amount of uncharged\nimatinib remaining for passive diffusion across cellular membrane.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Imatinib is not a substrate of OCTs 1-3 while the environmental pH modulates cellular\ndisposition of imatinib. The observation that a slightly acidic extracellular pH influences imatinib cellular\naccumulation is important, considering the low extracellular pH reported in the hematopoietic leukemia\/\ncancer cell microenvironment.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1872312813666190207150207","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T06:40:44Z","timestamp":1549608044000},"page":"102-110","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH"],"prefix":"10.2174","volume":"13","author":[{"given":"Jaur\u00e8s B.","family":"Mettral","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Faller","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Biology and Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cruchon","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Sottas","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Buclin","sequence":"additional","affiliation":[{"name":"Service of Clinical Pharmacology, Department of Laboratories, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Schild","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Biology and Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Choong","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimable","family":"Nahimana","sequence":"additional","affiliation":[{"name":"Research Laboratory of Haematology, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent A.","family":"Decosterd","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"Widmer N.","year":"2006","unstructured":"Widmer N.; Decosterd L.A.; Csajka C.; Leyvraz S.; Duchosal M.A.; Rosselet A.; Rochat B.; Eap C.B.; Henry H.; Biollaz J.; Buclin T.; Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006,62(1),97-112","journal-title":"Br J Clin Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","volume":"20","author":"Nies A.T.","year":"2014","unstructured":"Nies A.T.; Schaeffeler E.; van der Kuip H.; Cascorbi I.; Bruhn O.; Kneba M.; Pott C.; Hofmann U.; Volk C.; Hu S.; Baker S.D.; Sparreboom A.; Ruth P.; Koepsell H.; Schwab M.; Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res 2014,20(4),985-994","journal-title":"Clin Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"Widmer N.","year":"2008","unstructured":"Widmer N.; Decosterd L.A.; Leyvraz S.; Duchosal M.A.; Rosselet A.; Debiec-Rychter M.; Csajka C.; Biollaz J.; Buclin T.; Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008,98(10),1633-1640","journal-title":"Br J Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.bjc.6605584","volume":"102","author":"Widmer N.","year":"2010","unstructured":"Widmer N.; Decosterd L.A.; Csajka C.; Montemurro M.; Haouala A.; Leyvraz S.; Buclin T.; Imatinib plasma levels: correlation with clinical benefit in GIST patients. Br J Cancer 2010,102(7),1198-1199","journal-title":"Br J Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1182\/blood-2003-03-0993","volume":"102","author":"Widmer N.","year":"2003","unstructured":"Widmer N.; Colombo S.; Buclin T.; Decosterd L.A.; Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003,102(3),1142","journal-title":"Blood"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","volume":"14","author":"Hu S.","year":"2008","unstructured":"Hu S.; Franke R.M.; Filipski K.K.; Hu C.; Orwick S.J.; de Bruijn E.A.; Burger H.; Baker S.D.; Sparreboom A.; Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008,14(10),3141-3148","journal-title":"Clin Cancer Res"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052247","volume":"7","author":"Schmidt-Lauber C.","year":"2012","unstructured":"Schmidt-Lauber C.; Harrach S.; Pap T.; Fischer M.; Victor M.; Heitzmann M.; Hansen U.; Fobker M.; Brand S.M.; Sindic A.; Pavenst\u00e4dt H.; Edemir B.; Schlatter E.; Bertrand J.; Ciarimboli G.; Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis. PLoS One 2012,7(12)","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6e470","DOI":"10.1038\/bcj.2016.79","author":"Harrach S.","year":"2016","unstructured":"Harrach S.; Schmidt-Lauber C.; Pap T.; Pavenst\u00e4dt H.; Schlatter E.; Schmidt E.; Berdel W.E.; Schulze U.; Edemir B.; Jeromin S.; Haferlach T.; Ciarimboli G.; Bertrand J.; MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J 2016,6e470","journal-title":"Blood Cancer J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/leu.2015.170","volume":"29","author":"Watkins D.B.","year":"2015","unstructured":"Watkins D.B.; Hughes T.P.; White D.L.; OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia 2015,29(10),1960-1969","journal-title":"Leukemia"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"Thomas J.","year":"2004","unstructured":"Thomas J.; Wang L.; Clark R.E.; Pirmohamed M.; Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004,104(12),3739-3745","journal-title":"Blood"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"White D.L.","year":"2006","unstructured":"White D.L.; Saunders V.A.; Dang P.; Engler J.; Zannettino A.C.; Cambareri A.C.; Quinn S.R.; Manley P.W.; Hughes T.P.; OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006,108(2),697-704","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1182\/blood-2013-03-493841","volume":"121","author":"Burger H.","year":"2013","unstructured":"Burger H.; Mathijssen R.H.; Sparreboom A.; Wiemer E.A.; Can \u201cspecific\u201d OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib? Blood 2013,121(24),4965-4966","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"White D.L.","year":"2007","unstructured":"White D.L.; Saunders V.A.; Dang P.; Engler J.; Venables A.; Zrim S.; Zannettino A.; Lynch K.; Manley P.W.; Hughes T.; Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007,110(12),4064-4072","journal-title":"Blood"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3324\/haematol.2011.056457","volume":"97","author":"White D.L.","year":"2012","unstructured":"White D.L.; Radich J.; Soverini S.; Saunders V.A.; Frede A.K.; Dang P.; Cilloni D.; Lin P.; Mongay L.; Woodman R.; Manley P.; Slader C.; Kim D.W.; Pane F.; Martinelli G.; Saglio G.; Hughes T.P.; Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 2012,97(6),907-914","journal-title":"Haematologica"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/leu.2010.188","volume":"24","author":"White D.L.","year":"2010","unstructured":"White D.L.; Saunders V.A.; Dang P.; Engler J.; Hughes T.P.; OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia 2010,24(11),1962-1965","journal-title":"Leukemia"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"White D.L.","year":"2010","unstructured":"White D.L.; Dang P.; Engler J.; Frede A.; Zrim S.; Osborn M.; Saunders V.A.; Manley P.W.; Hughes T.P.; Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010,28(16),2761-2767","journal-title":"J Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/bjh.12591","volume":"163","author":"Grinfeld J.","year":"2013","unstructured":"Grinfeld J.; Gerrard G.; Alikian M.; Alonso-Dominguez J.; Ale S.; Valga\u00f1on M.; Nteliopoulos G.; White D.; Marin D.; Hedgley C.; O\u2019Brien S.; Clark R.; Goldman J.M.; Milojkovic D.; Apperley J.F.; Foroni L.; A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. Br J Haematol 2013,163(5),631-639","journal-title":"Br J Haematol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1200\/JCO.2011.41.1090","volume":"30","author":"White D.L.","year":"2012","unstructured":"White D.L.; Hughes T.P.; Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol 2012,30(10),1144-1145","journal-title":"J Clin Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2010-01-267013","volume":"116","author":"Engler J.R.","year":"2010","unstructured":"Engler J.R.; Frede A.; Saunders V.; Zannettino A.; White D.L.; Hughes T.P.; The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 2010,116(15),2776-2778","journal-title":"Blood"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12041-018-0978-9","volume":"97","author":"Makhtar S.M.","year":"2018","unstructured":"Makhtar S.M.; Husin A.; Baba A.A.; Ankathil R.; Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. J Genet 2018,97(4),835-842","journal-title":"J Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/sajc.sajc_244_17","volume":"7","author":"Chhikara S.","year":"2018","unstructured":"Chhikara S.; Sazawal S.; Singh K.; Chaubey R.; Pati H.; Tyagi S.; Mahapatra M.; Saxena R.; Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib. South Asian J Cancer 2018,7(4),258-262","journal-title":"South Asian J Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13046-017-0523-3","volume":"36","author":"Jaruskova M.","year":"2017","unstructured":"Jaruskova M.; Curik N.; Hercog R.; Polivkova V.; Motlova E.; Benes V.; Klamova H.; Pecherkova P.; Belohlavkova P.; Vrbacky F.; Machova Polakova K.; Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res 2017,36(1),55","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","volume":"79","author":"Ben Hassine I.","year":"2017","unstructured":"Ben Hassine I.; Gharbi H.; Soltani I.; Teber M.; Farrah A.; Ben Hadj Othman H.; Amouri H.; Bellaaj H.; Lakhal R.B.; Romdhane N.B.; Abbes S.; Menif S.; hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2017,79(4),737-745","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3892\/etm.2016.3127","volume":"11","author":"Yin C.X.","year":"2016","unstructured":"Yin C.X.; Chen W.W.; Zhong Q.X.; Jiang X.J.; Wang Z.X.; Li X.D.; Ye J.Y.; Cao R.; Liao L.B.; Wu F.Q.; Xu D.; Zhong J.S.; Meng F.Y.; Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia. Exp Ther Med 2016,11(5),2061-2065","journal-title":"Exp Ther Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","volume":"765","author":"Vaidya S.","year":"2015","unstructured":"Vaidya S.; Ghosh K.; Shanmukhaiah C.; Vundinti B.R.; Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia. Eur J Pharmacol 2015,765,124-130","journal-title":"Eur J Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000365437","volume":"133","author":"Cao C.","year":"2015","unstructured":"Cao C.; Li X.; Liu T.; Zhang L.; Shen K.; Zhu H.; Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia. Acta Haematol 2015,133(2),199-204","journal-title":"Acta Haematol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-5916.164250","volume":"142","author":"Malhotra H.","year":"2015","unstructured":"Malhotra H.; Sharma P.; Malhotra B.; Bhargava S.; Jasuja S.; Kumar M.; Molecular response to imatinib","journal-title":"Indian J Med Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","volume":"32","author":"Francis J.","year":"2015","unstructured":"Francis J.; Dubashi B.; Sundaram R.; Pradhan S.C.; Chandrasekaran A.; Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib. Med Oncol 2015,32(8),213","journal-title":"Med Oncol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1124\/mol.114.097451","volume":"88","author":"Burger H.","year":"2015","unstructured":"Burger H.; den Dekker A.T.; Segeletz S.; Boersma A.W.; de Bruijn P.; Debiec-Rychter M.; Taguchi T.; Sleijfer S.; Sparreboom A.; Mathijssen R.H.; Wiemer E.A.; Lysosomal Sequestration Determines Intracellular Imatinib Levels. Mol Pharmacol 2015,88(3),477-487","journal-title":"Mol Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1158\/1535-7163.MCT-06-0024","volume":"5","author":"Gerweck L.E.","year":"2006","unstructured":"Gerweck L.E.; Vijayappa S.; Kozin S.; Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006,5(5),1275-1279","journal-title":"Mol Cancer Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.4161\/15384101.2014.964107","volume":"13","author":"Rovida E.","year":"2014","unstructured":"Rovida E.; Peppicelli S.; Bono S.; Bianchini F.; Tusa I.; Cheloni G.; Marzi I.; Cipolleschi M.G.; Calorini L.; Sbarba P.D.; The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle 2014,13(20),3169-3175","journal-title":"Cell Cycle"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: the next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","volume":"877","author":"Haouala A.","year":"2009","unstructured":"Haouala A.; Zanolari B.; Rochat B.; Montemurro M.; Zaman K.; Duchosal M.A.; Ris H.B.; Leyvraz S.; Widmer N.; Decosterd L.A.; Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009,877(22),1982-1996","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"Crossman L.C.","year":"2005","unstructured":"Crossman L.C.; Druker B.J.; Deininger M.W.; Pirmohamed M.; Wang L.; Clark R.E.; hOCT 1 and resistance to imatinib. Blood 2005,106(3),1133-1134","journal-title":"Blood"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jps.20536","volume":"95","author":"Fujita T.","year":"2006","unstructured":"Fujita T.; Urban T.J.; Leabman M.K.; Fujita K.; Giacomini K.M.; Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006,95(1),25-36","journal-title":"J Pharm Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","volume":"10","author":"Minematsu T.","year":"2011","unstructured":"Minematsu T.; Giacomini K.M.; Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011,10(3),531-539","journal-title":"Mol Cancer Ther"},{"key":"ref=37","first-page":"1","volume":"2","author":"Rovida E.","year":"2014","unstructured":"Rovida E.; Marzi I.; Cipolleschi M.G.; Dello Sbarba P.; One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a \u201chypoxic\u201d environment. Hypoxia (Auckl) 2014,2,1-10","journal-title":"Hypoxia (Auckl)"}],"container-title":["Drug Metabolism Letters"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:03:12Z","timestamp":1581591792000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169753\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,15]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312813666190207150207","relation":{},"ISSN":["1872-3128"],"issn-type":[{"value":"1872-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"0219-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}